Duride may be part of symptomatic management applied in situations involving certain distressing symptoms related to physical discomfort in the chest.

The approved indications for this medicine include the prophylactic (preventive) treatment of angina pectoris (chest pain) associated with coronary artery disease. This means it may assist with managing symptom clusters that become more disruptive during flare-ups and is considered relevant to help with conditions characterized by periods of heightened symptoms.

As a long-acting nitrate, this medicine is applied in addressing conditions marked by increased physiological stress. The medication supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms. One patient-oriented benefit is that the medication may support the maintenance of a sense of stability when symptoms are more noticeable. The medicine may be part of symptomatic management relevant when supportive symptom management is appropriate and contributes to easing the overall symptom load.

Quick Fact: May provide supportive relief for Chest Discomfort

Regulatory References

1. Australian Therapeutic Goods Administration Product Information

Duride (Isosorbide Mononitrate) is officially established for use in adults and the elderly for the chronic prevention of angina pectoris. Its eligibility profile is strictly defined by government regulatory agencies based on clinical status and age.

Populations for Whom Use is Prohibited (Contraindications)

Official labeling contraindicates use in the following populations:

• Patients with known hypersensitivity to any organic nitrate (e.g., isosorbide mononitrate or dinitrate).
• Those with marked low blood pressure (systolic BP le 90 mm Hg), acute circulatory failure, circulatory collapse, or cardiogenic shock.
• Individuals with severe anaemia or conditions that increase intracranial pressure, such as cerebral haemorrhage.

Age-Specific and Conditional Eligibility

Population Group	Regulatory Status
Pediatric Patients (Under 18)	Not recommended; safety and efficacy have not been established.
Pregnancy and Lactation	Use is conditional; only if the potential benefit justifies the potential risk due to a lack of adequate human studies. Caution is advised during lactation.
Organ Impairment	Use requires caution and monitoring in patients with severe hepatic or severe renal impairment.

The medicine is not indicated for the treatment of an acute anginal attack; it is solely for prophylactic (preventive) use. Caution is also necessary for patients with certain heart conditions like hypertrophic obstructive cardiomyopathy.

Interactions with other medicines and products

This section describes officially documented interaction patterns based on government regulatory information for Duride (Isosorbide Mononitrate).

---

Formal Contraindicated Combinations

Co-administration of Duride is formally contraindicated with certain classes of medicines due to the risk of severe hypotension (dangerously low blood pressure). This restriction applies specifically to Phosphodiesterase Type 5 (PDE5) Inhibitors, such as Sildenafil, Tadalafil, and Vardenafil. The contraindication also extends to Soluble Guanylate Cyclase (sGC) Stimulators, such as Riociguat. Administration of a nitrate must not occur for a mandatory period of at least 24 hours following the administration of a PDE5 inhibitor.

---

Pharmacodynamic and Exposure Interactions

Co-administration with other Antihypertensive Agents (e.g., ACE Inhibitors, Beta-blockers) or other Vasodilators may result in additive hypotensive effects. Similarly, consumption of Alcohol (Ethanol) is officially documented to potentiate the blood pressure-lowering effect, increasing the risk of dizziness and fainting. Certain agents that affect the CYP3A4 enzyme, such as the inducer Apalutamide or the inhibitor Idelalisib, are documented to modify the plasma concentration of Duride, altering its systemic exposure. Cautions for interaction outcomes, such as severe hypotension, are specifically noted in regulatory documents for elderly patients.

The mechanism of Duride involves a molecular cascade that produces changes in vascular smooth muscle tone, altering cardiac demand. The action is mediated peripherally, relying on enzymatic conversion within vascular smooth muscle cells.

Bioactivation and NO Signaling Pathway

The drug functions as a prodrug that must be metabolized by the Mitochondrial Aldehyde Dehydrogenase ( mtALDH/ALDH2) enzyme. This bioactivation generates the active signaling molecule, Nitric Oxide ( NO). The NO then activates the enzyme Soluble Guanylate Cyclase ( sGC), initiating the primary signaling cascade by increasing the second messenger cyclic GMP ( cGMP). The elevation of cGMP promotes the relaxation of vascular smooth muscle.

Modulation of Vascular Tone and Workload

The cellular relaxation caused by cGMP results in widespread vasodilation, which preferentially affects the veins ( venodilation) over the arteries. This increased venous capacity reduces the volume of blood returning to the heart (Preload), and the arterial dilation lowers the resistance the heart must overcome (Afterload). The reduction in both Preload and Afterload constitutes the final physiological consequence of the mechanism: a change in Myocardial Oxygen Demand.

Constraint: Mechanism Limitation (Nitrate Tolerance)

The mechanism is subject to nitrate tolerance, a diminished vascular response observed with continuous exposure. This limitation is associated with the initial bioactivation step, specifically the functional capacity of the mtALDH/ALDH2 enzyme system, which affects the generation of the NO signal.

Administration Schedule and Constraints

Duride (Isosorbide Mononitrate Extended-Release Tablet) is administered on a once-daily oral schedule. The route of administration is oral for the extended-release tablet form. The timing is specific: the dose is taken in the morning upon awakening. This instruction is a procedural condition designed to establish a daily nitrate-free interval of approximately 10 to 14 hours, a pattern used for effective long-term management.

---

Dosing and Preparation

The dosing schedule for adults begins with an initial strength of 30 mg or 60 mg once daily. The typical maintenance range is 60 mg to 120 mg. Dose increases are implemented incrementally, requiring a minimum of three days on the current strength before any adjustment is made. In terms of preparation, the extended-release tablet is swallowed whole with fluid; the tablet is not to be crushed, chewed, or divided, as this would compromise its function. The medicine can be taken with or without food.

---

Population and Procedural Rules

No dose adjustment is typically required for older adult patients. Similar guidance applies to individuals with common changes in hepatic or renal function. The overall procedural structure involves the medicine's use as a long-term, chronic management tool, adhering to the morning schedule and the instruction for intact oral ingestion.

Research Evidence / Overview of Studies for Duride

---

Evidence for Use in Angina Pectoris Prevention

Research has examined Duride in clinical trials exploring how symptoms change over time for individuals with angina pectoris, a condition characterized by fluctuating or episodic manifestations of chest discomfort. These studies primarily involved comparing individuals taking Duride to those taking an inactive pill (placebo) or another standard treatment. The goal of this research was to see how Duride was observed in monitoring patterns related to the frequency of these acute or disruptive episodes.

The findings from these clinical studies suggest that Duride may contribute to understanding symptom patterns and how outcomes related to episodic or acute changes evolved. The research describes patterns where the studies reported patterns of differences in the number of periods of heightened symptom activity compared to those taking the placebo over the defined time intervals of the studies.

However, the results apply only to the populations studied in these clinical trial settings. While the evidence contributes to the broader evidence landscape, research exploring short-term symptom changes does not determine whether an individual will respond similarly. Comparative evidence against other available treatments remains limited.

---

Studies on Duride's Long-term Effects and Endurance

Studies have also monitored the use of Duride in long-term follow-up settings to evaluate its sustained presence. This research explores the durability of response—meaning whether the patterns observed in the short-term studies continue over many months or years.

The evidence so far describes patterns related to long-term observation in some individuals. These studies report how symptoms evolved in the observed populations during the extended duration. For some, research describes patterns related to outcomes linked to physical discomfort.

It is important to note that long-term effects are not fully established. Follow-up durations were limited in many studies, and there is limited information for long-term outcomes beyond the initial years of study. Research is ongoing to provide a more complete picture of what happens after many years of use.

---

Evidence in Different Groups of People

Research examined Duride in special populations to see if the findings describe patterns observed in the studies of the general population. This included studies that were applied in research contexts involving older adults and those with comorbid conditions that reflect systemic or functional imbalance.

Evidence was observed in some studies that findings for older adults may be similar to those in the general study population, although sample sizes were modest. For individuals with other health conditions, the research highlights changes measured during the study period, but evidence quality varies across studies, and data for certain groups remain insufficient.

For certain groups, such as children, pregnant or breastfeeding populations, or individuals with severe kidney or liver impairment, evidence is limited or entirely unavailable. The research provides context but not individual predictions for these groups, and study results reflect the specific conditions under which they were conducted.

---

What is Still Uncertain About Duride

Research for Duride was studied for the conditions characterized by fluctuating or episodic manifestations, yet a number of areas remain where more research is needed to provide full certainty.

The findings sometimes were mixed across different research groups, particularly concerning how outcomes related to daily functioning or activity level evolve over time. While some studies reported how symptoms evolved in the observed populations, others found different patterns, meaning certainty remains low in these specific areas.

The current body of evidence helps contextualize how patients reported their experience, but it highlights what is known—and what is still uncertain. Data are still emerging, and future research is needed to resolve conflicting findings and provide more robust evidence for all potential scenarios.

Key Studies & References

1. Treatment of angina pectoris with isosorbide-5-mononitrate. A multicenter study in general practice
2. DURIDE Product Information (Isosorbide mononitrate sustained release tablets) – Regulatory Monograph
3. DURIDE 60 mg Modified Release Tablet Data Sheet (Medsafe New Zealand)

Common questions about Duride (FAQ)

---

Q: What happens if you miss a dose of Duride?

If a dose is forgotten, official regulatory instructions describe that the dose is taken as soon as it is remembered. However, if it is nearly time for the next scheduled morning dose, the missed dose should be skipped entirely, and the regular schedule should be continued. Regulatory documents state that a double dose is not to be taken.

---

Q: What should be done if someone experiences a serious side effect from Duride?

Official safety information documents that if serious symptoms are experienced, such as breathing difficulty, rash, hives, or worsening chest pain, seeking immediate attention is noted as necessary. The official guidance instructs seeking emergency medical help or contacting a healthcare professional immediately.

---

Q: How does Duride affect the liver?

Official information indicates that Duride is processed, or metabolized, in the liver for the body to eliminate it. The medicine is processed by the liver but does not undergo the same initial filtering process that some other drugs experience.

---

Q: Why is the dosage of Duride sometimes adjusted?

Dose adjustments are part of the prescribed regimen to achieve the intended therapeutic effect while ensuring a daily rhythm that avoids a problem called tolerance. Tolerance is when the medicine may stop working as effectively over time. Official prescribing information also notes that the starting strength may be lower for older adult patients.

---

Q: How is the long-term safety of Duride monitored?

Regulatory guidance indicates that the long-term use of this medicine is monitored by keeping track of specific physical measurements. This typically includes regular checks of a person's blood pressure and heart rate by a healthcare professional.

---

Q: What is the difference between Duride and a vitamin or supplement?

Duride is a prescription-only, synthetic medication that is formally classified by government health agencies as an Antianginal Agent and a Nitrate Vasodilator. This classification means it is a heavily regulated medicine with a defined physiological action, which distinguishes it from dietary vitamins or supplements.

---

Q: Is it safe to drink alcohol while taking Duride?

Official documentation describes that consuming alcohol increases the risk of low blood pressure, a condition known as hypotension. This effect can increase the chance of experiencing associated effects like dizziness, light-headedness, or fainting.

---

Q: Is it true that Duride is approved for treating [main condition]?

The medicine is officially approved for the chronic prevention of angina pectoris (chest pain) due to coronary artery disease. It is not indicated for treating an acute episode.

---

Q: Does Duride interact with common over-the-counter pain relievers?

Official information advises that common pain relievers like acetaminophen (the active ingredient in Tylenol) may be used to treat headaches that sometimes occur when starting the medication. No interaction has been officially reported with this common pain reliever.

---

Q: How long can a person safely take Duride?

Duride is prescribed as a long-term, chronic management tool that requires consistent daily use. Official regulatory studies caution against abrupt discontinuation after long-term use, as this may cause a return of the original symptoms.

---

Q: Does Duride affect blood pressure?

Yes, regulatory information states that the drug is a vasodilator and causes a reduction in systolic blood pressure. The regulatory label notes this effect is considered dose-dependent.

---

Q: Is Duride a new medicine, or has it been around for a while?

The active ingredient in Duride, isosorbide mononitrate, is a well-established compound. It was patented in 1971 and approved for medical use in 1981, indicating it has been available for use for many decades.

---

Q: What type of healthcare professional can prescribe Duride?

Duride is officially classified as a prescription-only (Rx only) medication. This means it can only be obtained with a prescription from a licensed healthcare professional.

---

Q: Can Duride cause weight changes?

Official regulatory safety profiles and adverse reaction lists do not include weight changes. Weight gain or loss is not listed as a commonly or rarely reported side effect for this medication.

---

Q: Is there a generic version of Duride available?

Yes, the Food and Drug Administration (FDA) has approved generic versions of the long-acting isosorbide mononitrate tablet. The generic form contains the same active ingredient and meets the same quality standards as the brand-name product.

---

Q: Why do people sometimes stop taking Duride?

Official documents note that some people may discontinue treatment due to side effects or a loss of effectiveness over time. This loss of effectiveness is a phenomenon called tolerance, which is a known constraint related to how the medicine works.

---

Q: Does the time of day matter when taking Duride?

Yes, the official schedule is very specific, typically requiring the dose to be taken upon waking in the morning. This timing is a condition used to establish a daily nitrate-free interval (around 10 to 14 hours) that helps the medicine maintain its intended effect.

---

Q: Can Duride be used alongside a specific diet?

Official guidance generally advises patients to continue their normal diet unless their healthcare provider recommends otherwise. The medicine can be taken either with food or on an empty stomach.

---

Q: Is Duride a commonly prescribed medication?

Yes, official dispensing data indicates that the active ingredient in Duride is one of the most frequently used medications in the United States. It is widely prescribed according to recent usage statistics.

---

Q: What is the role of Duride in a broader treatment plan?

Duride is prescribed as a chronic, long-term therapy for the prevention of angina pectoris. Official research confirms it is designed to be a component of a comprehensive medical approach that may be used alongside other prescribed heart medicines.

---

Q: Are there specific genetic factors that affect how Duride works?

Research has been conducted to examine how certain genetic factors may influence the body's cardiovascular response to this medication. These studies provide context on how the drug is processed, which may differ among individuals.

---

Q: Where is the evidence for Duride published?

Official regulatory evidence, including clinical trial summaries and drug data, is published by government health agencies. This information is available through resources like the FDA drug approval documents and the DailyMed database.

Storage and Disposal Requirements for DURIDE (Isosorbide Mononitrate)

Official regulatory guidelines define precise conditions for storing and disposing of DURIDE tablets.

---

Required Storage Conditions

Requirement	Specific Condition
Temperature	Store at or below 30°C in a cool, dry place.
Protection	Protect the medicine from heat and dampness; do not store in areas like the bathroom, near a sink, or in a car.
Container	Keep tablets in the original pack until the time of use to ensure product stability.
Child Safety	Must be kept out of the sight and reach of children.

---

Official Disposal Instructions

Expired, unused, or damaged DURIDE tablets must be handled according to specific local guidelines. Regulatory instructions require that the product be returned to a pharmacist for proper disposal. If return is not possible, follow national guidelines for non-hazardous medicinal waste, such as mixing the product with an undesirable substance, sealing it, and placing it in household trash.